Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial combines four different treatments at once — thermal therapy, a KRAS G12V mRNA vaccine, the chemotherapy drug S-1, and an immunotherapy called sintilimab — so what does my doctor think the combined side effect burden might look like for someone in my situation, and how would that compare to my current standard-of-care options?
2. 2Since this is a Phase 2 trial and it's not yet recruiting, the primary goal is still largely about measuring safety and how often doses need to be adjusted or stopped — does my doctor think the safety profile of this combination is well enough understood that participating would be a reasonable choice, or would it make more sense to try established treatments first?
3. 3The KRAS G12V mRNA vaccine is designed to target a specific genetic mutation — has my tumor actually been tested for the KRAS G12V mutation, and if not, would that testing need to happen before we could even seriously consider this trial?
4. 4The trial targets metastatic pancreatic cancer involving the liver and lungs — given where my cancer has spread, does my doctor think the multimodal thermal therapy component would be practically applicable to my specific metastatic pattern?
5. 5Since this trial isn't recruiting yet, what is the realistic timeline before it might open, and given how quickly pancreatic cancer can progress, does my doctor think it's worth waiting or pursuing another treatment path in the meantime?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.